Veratrine sulfate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Veratrine sulfate
• 英文别名: [(1R,2S,6S,9S,10R,11S,12S,14R,15S,18S,19S,22S,23S,25R)-1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] (Z)-2-methylbut-2-enoate;sulfuric acid
• 化学式: C32H51NO13S
• 分子量: 689.8
• InChiKey: OSAVSKIZUCPUJG-ZLVREPKBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.34
• 重原子数：
  47
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  243
• 氢给体数：
  8
• 氢受体数：
  14

文献信息

• Theranostics platform and methods of use
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10161929B2

  公开（公告）日：2018-12-25

  Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library.

  本文描述了用于识别治疗罕见病的药物和营养保健品的血清学平台。这些平台包括：(a) 细胞表型图像增强仪器；(b) 药物/营养保健品库；(c) 计算机实施系统，用于分析光学可视罕见疾病细胞表型对药物/营养保健品库中药物或营养保健品的反应。
• CARDIOVASCULAR COMPOSITION AND USE THE SAME FOR THE TREATMENT OF ALZHEIMERS DISEASE
  申请人：Mount Sinai School of Medicine

  公开号：EP2007385A2

  公开（公告）日：2008-12-31
• Protein Kinase C Iota
  申请人：Fields P. Alan

  公开号：US20070283451A1

  公开（公告）日：2007-12-06

  The invention involves PKCι signaling. The invention provides, for example, transgenic animals, inhibitors of PKCι signaling, methods for inhibiting PKCι signaling, methods for identifying inhibitors of PKCι signaling, and methods for diagnosing cancer.
• CARDIOVASCULAR COMPOSITIONS AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：Pasinetti Giulio

  公开号：US20100029654A1

  公开（公告）日：2010-02-04

  Methods and compositions for the treatment of Alzheimer's Disease are described. More specifically, the invention demonstrates that administration of cardiovascular agents to a mammal suffering from the symptoms of Alzheimer's Disease causes an amelioration of those symptoms. The finding of the present invention can be used in treatment regimens designed to attenuate or prevent Alzheimer's Disease.
• PROTEIN KINASE C IOTA
  申请人：Fields Alan P.

  公开号：US20100092578A1

  公开（公告）日：2010-04-15

  The invention involves PKC ι signaling. The invention provides, for example, transgenic animals, inhibitors of PKC ι signaling, methods for inhibiting PKC ι signaling, methods for identifying inhibitors of PKC ι signaling, and methods for diagnosing cancer.